Catalysts for Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd — (clascoterone + latanoprost) (Phase II Trial Initiation)

LAMOTRIGINE — FDA approval

LAMOTRIGINE — FDA approval

LAMOTRIGINE — FDA approval

PROGESTERONE — FDA approval

FLUTICASONE PROPIONATE — FDA approval

LACOSAMIDE — FDA approval

TOPIRAMATE — FDA approval

FINGOLIMOD HYDROCHLORIDE — FDA approval

SUCRALFATE — FDA approval

TOPIRAMATE — FDA approval

TACROLIMUS — FDA approval

TACROLIMUS — FDA approval

TACROLIMUS — FDA approval

TACROLIMUS — FDA approval

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval

LAMOTRIGINE — FDA approval

FINGOLIMOD HYDROCHLORIDE — FDA approval

FINGOLIMOD HYDROCHLORIDE — FDA approval

TOPIRAMATE — FDA approval

LAMOTRIGINE — FDA approval

LAMOTRIGINE — FDA approval

TOPIRAMATE — FDA approval

TOPIRAMATE — FDA approval

TOPIRAMATE — FDA approval

TOPIRAMATE — FDA approval

TOPIRAMATE — FDA approval

TOPIRAMATE — FDA approval